About Eduardo Candelario-Jalil
Dr. Eduardo Candelario-Jalil received his Ph.D. in Pharmacology from the University of Havana, Cuba, in 2002. He did his first postdoctoral training in the Department of Psychiatry at the University of Freiburg, Germany. He studied the signal transduction pathways responsible for cyclooxygenase (COX)-2 upregulation in primary microglial cells and neurons during neuroinflammatory conditions and cerebral ischemia. He joined the University of New Mexico, USA, in 2006 to pursue his second postdoctoral training with Dr. Gary A. Rosenberg and later became a Research Assistant Professor in the Department of Neurology at the University of New Mexico in 2008. After successfully obtaining an R01 grant from the National Institutes of Health (NIH) in 2011, Dr. Candelario-Jalil moved to the University of Florida on a tenure-track faculty position in the Department of Neuroscience, McKnight Brain Institute. In July 2019, Dr. Candelario-Jalil was promoted to Associate Professor with tenure at the University of Florida.
Dr. Candelario-Jalil’s research interests have been fostered by many years of work in neuropharmacology, biochemistry, and molecular biology. Dr. Candelario-Jalil’s postdoctoral training in Germany and the United States focused upon elucidating the mechanisms underlying the neuroprotective ability of cyclooxygenase-2 (COX-2) inhibitors in experimental animal models of ischemic injury (focal ischemic stroke induced by middle cerebral artery occlusion and global forebrain ischemia). His current research activities are focused on identifying the downstream prostaglandin E2 (PGE2) receptors involved in ischemic brain injury and neuroinflammatory mechanisms responsible for the late opening of the blood-brain barrier following stroke. Other research areas in Dr. Candelario-Jalil’s laboratory include investigating neurovascular effects of adropin, a recently identified peptide, in animal models of ischemic stroke. Moreover, another main project involves the study of the role of bromodomain and extraterminal domain (BET) proteins in the neuroinflammatory response to ischemic stroke.
Dr. Candelario-Jalil directs an active research program with great translational potential, funded by two R01 grants from the NIH. Research is focused on understanding neuroinflammatory mechanisms following ischemic stroke utilizing biochemical, cellular, genetic, pharmacological, and MRI multimodal approaches. As encouraged by the NIH/NINDS Roadmap, this type of translational research is of fundamental importance in accelerating the development of effective stroke therapeutics.
Dr. Candelario-Jalil has authored 72 original peer-reviewed publications, 11 invited review articles, and 3 book chapters. He has made significant contributions to the understanding of neuroinflammatory mechanisms in ischemic stroke, as demonstrated by several research articles published in high-profile and prestigious journals in the field such as Stroke, Journal of Neurochemistry, Journal of Neuroscience, Journal of Cerebral Blood Flow and Metabolism, Journal of Pharmacology & Experimental Therapeutics, and Journal of Neuroinflammation. Dr. Candelario-Jalil’s work has been extensively cited with an h-index of 35.
- Advanced MRI and stroke
- Blood biomarkers and stroke
- Neuroimmune interactions in Neurodegenerative diseases
- Protective and preventive measures of cerebrovascular disorders (cerebral ischemia, vascular remodeling and neurological imaging)
- Stroke recovery
- cerebral ischemia